Full and Open Competition · 29 offers
Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Silver Spring, MD 20910, USA
Award details come from SAM.gov/FPDS.
Transactions
Action
Obligated
Date
Close Out
P00033 · To DE-obligate remaining funds and administratively close the contract.
-$69,278
Funding Only Action
P00032
-$257
Funding Only Action
P00031 · A broad spectrum, host based antiviral drug for biodefense
$1,219,399
Funding Only Action
P00030 · To RE-obligate funds to pay allowable costs in the amount of $69,278.33 under option 6
$69,278
Funding Only Action
29 · To deobligate expiring FY13 funds in the amount of $21,879.18
-$21,879
Other Administrative Action
28 · To extend the expiration date of option 4 from september 29, 2017 to september 29, 2018.
$0
Funding Only Action
27 · To deobligate $74416.18 from option 6.
-$74,416
Other Administrative Action
26 · To remove DR. Aruna sampath from article g.2. Key personnel, as principal investigator, and replace with DR. Kelly warfield, principal investigator. To add…
$0
Change Order
25 · To remove the phase i MAD trial from option 3 of the contract. Emergent will complete all activities associated with cohort 1 only. Niaid will complete…
$0
Other Administrative Action
24 · To modify article b.4.b.1 travel costs domestic travel, to increase the option 3 budget amount to $43,469.65. To modify article c.2. Reporting requirements,…
$0
Other Administrative Action
23 · To extend the expiration date of option 4 from december 31, 2016 to september 29, 2017. To extend the expiration date of option 6 from december 31, 2016 to…
$0
Other Administrative Action
22 · Beginning with the effective date of this modification, the parties mutually agree to extend the expiration date of option 6 from april 30, 2016 to december 31,…
$0
Vendor Address Change
21 · To recognize the contractor's name change to emergent virology LLC and to update the POC information for the CO and COR.
$0
Funding Only Action
20
$3,413,181
Other Administrative Action
19
$0
Other Administrative Action
18
$0
Other Administrative Action
17
$0
Other Administrative Action
15 · 1100030C unither - DEV of therapeutic products
$0
Other Administrative Action
14 · Purpose: beginning with the effective date of this modification, the parties mutually agree to extend the expiration date of the base period from march 29, 2015…
$0
Other Administrative Action
16 · 1100030C unither - DEV of therapeutic products
$0
Other Administrative Action
13 · Beginning with the effective date of this modification, the parties mutually agree to extend the expiration date of option 3 from february 28, 2015 to…
$0
Funding Only Action
11
$230,713
Change Order
12 · Purpose: to fund an overrun.beginning with the effective date of this modification, the parties mutually agree to the revisions stated on pages one and…
$85,047
Exercise an Option
10 · Purpose: to exercise option 4. Beginning with the effective date of this modification, the contract is changed as reflected below. The total estimated cost is…
$2,098,226
Other Administrative Action
9 · Purpose: beginning with the effective date of this modification, the government and contractor mutually agree to the following:the period of performance of…
$0
Other Administrative Action
8 · Purpose: to remove DR. Urban ramstedt, PI, from article g.2. Key personnel, and replace with DR. Matthew duchars, PI, and DR. Aruna sampath, program manager.…
$0
Exercise an Option
7 · To exercise option 3. Beginning with the effective date of this modification, the contract is changed as reflected below. The total estimated cost is…
$4,565,457
Funding Only Action
6 · Purpose: to fund an overrun.the total funded amount of this task order is increased by $465,355 from $10,556,375 to $11,021,730.
$465,355
Other Administrative Action
5 · Purpose: beginning with the effective date of this modification, the parties mutually agree to add alternate II (december 2007), far clause 52.227-14, rights in…
$0
Other Administrative Action
4
$1,430,187
Exercise an Option
3 · Title: a broad spectrum, host base antiviral drug for biodefense.
$0
Other Administrative Action
2 · Purpose: amend article g.1. To assign TAM nguyen, PH.d., as the alternate cotr. Rosemarie aurigemma, PH.d., is removed as the alternate cotr.
$0
Exercise an Option
1 · Purpose: to exercise option 1 and 6. Beginning with the effective date of this modification, the contract is changed as reflected on pages 1 through 4. The…
$8,682,294
Original award
$10,556,375
Show all 34
Quick answers
Who was awarded contract HHSN272201100030C?
HHSN272201100030C was awarded to Emergent Virology, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 27, 2011.
How much is contract HHSN272201100030C worth?
The government has obligated $32,649,682 on HHSN272201100030C. Its potential value, with all options, is $50,185,383.
Was contract HHSN272201100030C competed?
The extent of competition for HHSN272201100030C was full and open competition. The government received 29 offers.
Emergent Virology, LLC UEI GMUKDDR5TMU7 Part of Emergent Biosolutions Inc.
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services